PRE-MARKET CHINESE STOCK NEWS: Huaxin Building Materials agrees to acquire CSN Cimentos, Innovent reports positive Phase 3 trial results
ORIGINAL · NewsquawkPRE-MARKET CHINESE STOCK NEWS: Huaxin Building Materials agrees to acquire CSN Cimentos, Innovent reports positive Phase 3 trial resultsRead originalHide original
Huaxin Building Materials Group (6655 HK) - Co. agrees to acquire a 99.99% stake in Brazil's CSN Cimentos for USD 1.64bln, marking the first entry by a Chinese company into Brazil's cement market, according to exchange filings. (SCMP) Innovent Biologics (1801 HK) - Co.'s Phase 3 study of cholesterol-lowering drug Sintbilo met its primary endpoint, with monotherapy demonstrating significant lipid-lowering efficacy and favourable safety and tolerability. Plans to submit a new indication application in the near future, with potential approval offering a new first-line treatment option for hyperlipidemia patients in China. (Innovent Biologics) Xtalpi (2228 HK) - Units enter a research collaboration agreement with Pierre Fabre Médicament SAS to discover novel clinical candidates in oncology, dermatology and rare diseases. (Newswires) Other News: China's NDRC flagged weak domestic demand as a key economic challenge, with Director Zheng Shanjie pledging measures to boost private investment, advance major projects, strengthen economic monitoring and develop further policy proposals for next year. China's State Council called for measures to ensure full-year economic targets are met, effective use of policy-oriented funds, stronger stock market stability and sustained economic development, according to state media. The PBoC added 830k ounces of gold to its reserves in October, extending its buying streak to 24 consecutive months. Chinese Foreign Exchange Reserves (Oct) 3.405T (Prev. 3.400T)
The brief reports company transactions and trial news alongside Chinese policy statements and October reserve data; retrieved evidence corroborates some, but not all, of these items.
News detail
Huaxin Building Materials Group (6655 HK) - Co. agrees to acquire a 99.99% stake in Brazil's CSN Cimentos for USD 1.64bln, marking the first entry by a Chinese company into Brazil's cement market, according to exchange filings. (SCMP) Innovent Biologics (1801 HK) - Co.'s Phase 3 study of cholesterol-lowering drug Sintbilo met its primary endpoint, with monotherapy demonstrating significant lipid-lowering efficacy and favourable safety and tolerability. Plans to submit a new indication application in the near future, with potential approval offering a new first-line treatment option for hyperlipidemia patients in China. (Innovent Biologics) Xtalpi (2228 HK) - Units enter a research collaboration agreement with Pierre Fabre Médicament SAS to discover novel clinical candidates in oncology, dermatology and rare diseases. (Newswires) Other News: China's NDRC flagged weak domestic demand as a key economic challenge, with Director Zheng Shanjie pledging measures to boost private investment, advance major projects, strengthen economic monitoring and develop further policy proposals for next year. China's State Council called for measures to ensure full-year economic targets are met, effective use of policy-oriented funds, stronger stock market stability and sustained economic development, according to state media. The PBoC added 830k ounces of gold to its reserves in October, extending its buying streak to 24 consecutive months. Chinese Foreign Exchange Reserves (Oct) 3.405T (Prev. 3.400T)
What do investors think?
StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.